Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

Bone Marrow Transplant. 2019 May;54(5):746-748. doi: 10.1038/s41409-018-0362-7. Epub 2018 Oct 18.

Authors

Panayotis Kaloyannidis¹, Eshrak Al Shaibani², Ioannis Apostolidis², Solaf Kanfar², Khalid Al Anezi², Hani Al Hashmi²

Affiliations

¹ Adults Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia. pkaloyannidis@yahoo.gr.
² Adults Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Bortezomib / administration & dosage*
Chronic Disease
Drug Therapy, Combination
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology
Graft vs Host Disease / pathology
Humans
Lymphoma, T-Cell / therapy
Male
Nitriles
Pyrazoles / administration & dosage*
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
Bortezomib
ruxolitinib